Komori
Business Alliance4591RIBOMIC Inc.Pharmaceuticals

Notice of Termination of Joint Research and Development Agreement with 三菱商事ライフサイエンス株式会社

The joint research and development agreement with 三菱商事ライフサイエンス株式会社 concerning candidate cosmetic ingredients will be terminated on 31 March 2026. The joint research has resulted in the creation of aptamers and the joint filing of patent applications. The parties will discuss the handling and use of the patent rights going forward.

Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Agreements reached under this partnership

Discontinuation
4591RIBOMIC Inc.
Alliance partner三菱商事ライフサイエンス株式会社
Details of the alliance
  1. 1

    Creation of aptamers as candidate cosmetic ingredients

  2. 2

    Discussion and consideration with the company of policies concerning the handling and use of the jointly filed patent rights, including the granting of licenses to third parties

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionManufacture, processing, sale and purchase, import and export, and research and development of seasonings, sugar alcohols, sweeteners, quality improvers, yeast extracts, yeast-related materials, confectionery alcohol products, health ingredients, cosmetics and other products
LocationChiyoda-ku, Tokyo
Share capital¥1,399 million
Impact on Business Performance

This matter will have no impact on full-year results for the fiscal year ending March 2026.

Contract Date18 January 2019Contract PeriodThe agreement entered into on 18 January 2019 will be terminated on 31 March 2026
Agreements reached under this partnership
ItemDetails
Name of alliance partner三菱商事ライフサイエンス株式会社
Alliance partner's business activitiesManufacture, processing, sale and purchase, import and export, and research and development of seasonings, sugar alcohols, sweeteners, quality improvers, yeast extracts, yeast-related materials, confectionery alcohol products, health ingredients, cosmetics and other products
Alliance partner's locationChiyoda-ku, Tokyo
Alliance partner's capital¥1,399 million
Type of allianceDiscontinuation
Details of the allianceCreation of aptamers as candidate cosmetic ingredients, Discussion and consideration with the company of policies concerning the handling and use of the jointly filed patent rights, including the granting of licenses to third parties
Contract PeriodThe agreement entered into on 18 January 2019 will be terminated on 31 March 2026
Contract Date18 January 2019
Impact on Business PerformanceThis matter will have no impact on full-year results for the fiscal year ending March 2026.
Items this document does not state (14)
Alliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The prescribed aptamers have been created and the joint filing of patent applications based on the results of the joint research has been completed, producing certain results and bringing the joint research to a natural conclusion.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Termination of Joint Research and Development Agreement with 三菱商事ライフサイエンス株式会社 | RIBOMIC Inc. (4591) timely disclosure | Komori